Product Name: Saftaz 1.125
Composition: Cefoperazone Sodium 1000 mg + Tazobactam Sodium 125 mg
Dosage Form: Injection (for IV/IM use)
Therapeutic Category: Third-Generation Cephalosporin with -lactamase Inhibitor
Saftaz 1.125 is a powerful combination of Cefoperazone, a third-generation cephalosporin antibiotic, and Tazobactam, a -lactamase inhibitor. Cefoperazone inhibits bacterial cell wall synthesis, while Tazobactam extends its spectrum by inhibiting -lactamase enzymes that can degrade cefoperazone. Together, they provide enhanced activity against a wide range of Gram-positive and Gram-negative bacteria, including -lactamase-producing strains.
Lower respiratory tract infections
Urinary tract infections
Intra-abdominal infections
Septicemia
Skin and soft tissue infections
Gynecological and obstetric infections
Post-surgical infections
Broad-spectrum antibacterial coverage
Effective against resistant -lactamase-producing organisms
Suitable for serious and hospital-acquired infections
Reliable safety and tolerability profile
As prescribed by the physician. Typically administered via IV or IM route.
Price: